 Home > Medical News > Latest Medical News > Pharmaceutical machine enterprises have increased investment in research and development, and product performance and capacity expansion are accelerating

Pharmaceutical machine enterprises have increased investment in research and development, and product performance and capacity expansion are accelerating

 Last Update: 2022-10-02
 Source: Internet
 Author: User

Tags

laboratory scale

high quality binders

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In order to maintain a competitive advantage, Chinese pharmaceutical companies have increased their investment
in product research and development in recent years.

Pharmaceutical machinery enterprises increase investment, product performance and capacity expansion continue to accelerate (picture source: pharmaceutical network)

It is worth mentioning that a number of pharmaceutical companies have invested more than 1 billion yuan in innovation, in addition to the above-mentioned BeiGene Shenzhou, China Biopharmaceuticals, including Hengrui, Junshi Biologics, CSPC, and Huang Pharmaceutical
.
At present, with the increasing investment in innovation and research and development of pharmaceutical companies, new treatment methods such as targeted drugs and biological macromolecules have also begun to appear
.
It is worth noting that in this context, in addition to pharmaceutical companies, the upstream pharmaceutical equipment market has also ushered in more new additions
.

Data combing shows that in the first half of this year, the profit growth rate of the pharmaceutical equipment industry was maintained at about 10%, and the revenue and net profit growth rate of the industry leader was higher, such as in the first half of the year, Canaan Technology achieved revenue of 493.
8 million yuan, an increase of 14.
33% year-on-year; Net profit was 42.
3643 million yuan, an increase of 12.
63%
year-on-year.
In addition, Chutian Technology and Dongfulong both achieved a revenue growth of more than 20%, and the net profit increased
significantly.
Specifically, Chutian Technology achieved revenue of about 2.
871 billion yuan in the first half of the year, an increase of 20.
04% year-on-year; Net profit was about 299 million yuan, an increase of 26.
74%
year-on-year.
Dongfulong achieved revenue of about 2.
43 billion yuan, an increase of 34.
11% year-on-year; Net profit was about 400 million yuan, an increase of 18.
33%
year-on-year.

The industry believes that in the future, with the intensification of the aging of the population, the continuous upgrading of consumption, and the rapid development of markets such as biological drugs, innovative drugs and pharmaceutical outsourcing, the demand for pharmaceutical equipment market will continue to expand
.
It is estimated that by 2025, the scale of China's pharmaceutical equipment market will reach about 87.
5 billion yuan (excluding consumables, auxiliary materials, etc.
), with a compound growth rate of about 10.
22%
from 2020 to 2025.

However, it should be noted that with the growing demand for high-end medical equipment in the pharmaceutical market, domestic pharmaceutical equipment also needs to accelerate iterative upgrading
.
It is understood that in January 2022, the Ministry of Industry and Information Technology and other nine departments jointly issued the "14th Five-Year" Pharmaceutical Industry Development Plan, which has focused on the in-depth implementation of intelligent manufacturing, green manufacturing and quality improvement actions, improving the quality management level and product quality of the whole life cycle of drugs and medical devices, and promoting the high-end, intelligent and green development of
the pharmaceutical industry.

In fact, at present, there are many domestic pharmaceutical equipment with research and development strength and capital that have been accelerating the development of product performance and capacity expansion by increasing investment in innovation and research and development
, diversifying and differentiating equipment and technology.
It is understood that Dongfulong recently issued a prospectus for the issuance of A-shares to specific targets in 2022
.
According to the announcement, the total amount of funds raised by the issuance of shares to specific targets does not exceed 3.
2 billion yuan (including this number), which is intended to be used to invest in the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, the Zhejiang Dongfulong Biotechnology Co.
, Ltd.
life science industrialization base project and supplementary working capital
.

Previously, Canaan Technology also announced that it intends to invest 50 million yuan in its own funds to establish a wholly-owned subsidiary, Tianjin Canaan Biomedical Equipment Co.
, Ltd.
(hereinafter referred to as "Tianjin Canaan"
).
The announcement shows that this foreign investment is an important part of the company's extension of the biopharmaceutical equipment industry chain, which is conducive to the horizontal expansion of the company's biological pharmaceutical equipment and enhances the company's market competitiveness and sustained profitability
.

In addition, Singapore and Malaysia Pharma is building a pharmaceutical equipment industrialization project
.
After the completion of the project, it will form a solid preparation-laboratory, customized, production-type, airtight production line of the whole industrial chain
.
It is expected that the sales revenue will reach 1.
2 billion yuan, the annual profit will be 180 million yuan, the annual tax will be 52 million yuan, and the number of new jobs will be 500 people
.

In general, under the continuous investment of pharmaceutical machinery enterprises, their product performance and capacity expansion are constantly accelerating, and in the future, affected by this, the company's own market competitiveness will continue to improve, and import substitution may also accelerate
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.